Provided by Tiger Trade Technology Pte. Ltd.

Avalo Therapeutics Inc

14.68
-0.2700-1.81%
Volume:415.60K
Turnover:6.09M
Market Cap:787.29M
PE:-3.33
High:15.16
Open:15.16
Low:14.31
Close:14.95
52wk High:24.27
52wk Low:12.41
Shares:53.63M
Float Shares:40.15M
Volume Ratio:0.44
T/O Rate:1.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4100
EPS(LYR):-5.8400
ROE:-36.27%
ROA:-18.50%
PB:1.75
PE(LYR):-2.51

Loading ...

Avalo Chief Legal Officer Paul Varki disposes of common shares worth $1.49 million

Reuters
·
May 08

Avalo Therapeutics director Mitchell Chan sells 3,167 shares for $72,478.96

Reuters
·
May 08

Guggenheim Keeps Their Buy Rating on Avalo Therapeutics (AVTX)

TIPRANKS
·
May 07

Stifel Nicolaus Reaffirms Their Buy Rating on Avalo Therapeutics (AVTX)

TIPRANKS
·
May 06

BUZZ-U.S. STOCKS ON THE MOVE-Walt Disney, CVS, Uber

Reuters
·
May 06

BUZZ-U.S. STOCKS ON THE MOVE-AMD, Apollo, Deckers Outdoor

Reuters
·
May 06

BUZZ-Avalo jumps after skin disease drug shows potential benefit in mid-stage trial

Reuters
·
May 06

Avalo Therapeutics Shares Jump 43.5% Premarket After Co's Skin Disease Drug Meets Mid-Stage Trial Goal

THOMSON REUTERS
·
May 06

Julian Harrison Raises AVTX Price Target to $58 on Strong Phase 2 LOTUS Data and Differentiated Safety Profile for Abdakibart

TIPRANKS
·
May 06

U.S. RESEARCH ROUNDUP-IBM, Lumentum Holdings, TransDigm Group

Reuters
·
May 06

Avalo Therapeutics prices USD 375 million follow-on offering at USD 17.75/share

Reuters
·
May 06

Avalo Therapeutics Inc - Shares Sold at $17.75 per Share

THOMSON REUTERS
·
May 06

Avalo Therapeutics Announces Pricing of $375 Million Public Offering

THOMSON REUTERS
·
May 06

Avalo Therapeutics announces common stock and warrants offering, no amount given

TIPRANKS
·
May 06

Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire
·
May 06

Avalo reports Phase 2 LOTUS trial meets primary endpoint for HS drug abdakibart

Reuters
·
May 06

Avalo Therapeutics Inc - Reports Statistically Significant Benefit on Key Secondary Endpoints in Phase 2 Lotus Trial

THOMSON REUTERS
·
May 06

Avalo Therapeutics Inc - Phase 2 Lotus Trial Meets Primary Endpoint With 42.2% and 42.9% Response Rates at Week 16

THOMSON REUTERS
·
May 06

Avalo Therapeutics Inc - Abdakibart Well Tolerated With Favorable Safety Profile in Phase 2 Lotus Trial

THOMSON REUTERS
·
May 06

Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa

GlobeNewswire
·
May 06